It is critical to investigate both TP53 mutation and BCL2 rearrangement in MYC translocation positive DLBCL, and to distinguish double‐hit DLBCLs from those with an isolated MYC translocation in routine clinical practice. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.